Log In
BCIQ
Print this Print this
 

Anti-IL13, lebrikizumab (MILR1444A, RG3637) (formerly TNX-650)

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionHumanized mAb targeting IL-13
Molecular Target Interleukin-13 (IL-13)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/12/2011

Undisclosed

0

Undisclosed

Get a free BioCentury trial today